Japan First in the World to Approve Dupixent® (dupiluma

Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved indication for Dupixent in Japan and the sixth indication for...

Related Keywords

Japan , Paris , France General , France , Japanese , Sally Bain , Evan Berland , Arnaud Delepine , Nathalie Pham , Georged Yancopoulos , Corentine Driancourt , Regeneron Velocimmune , Tarik Elgoutni , Felix Lauscher , Vesna Tosic , Ilana Yellen , Eva Schaefer Jansen , Linkedin , Regeneron Genetics Center , Dupilumab Development Program , Exchange Commission , Ministry Of Health , Euronext , Regeneron Pharmaceuticals Inc , Regeneron Velocimmune Technology , Nasdaq , Chief Scientific Officer George , Nasal Polyposis , Prescribing Information , Forward Looking Statements , Regeneron Pharmaceuticals , Product Candidates , Private Securities Litigation Reform Act , Statement Regarding Forward Looking , Markets ,